MX2010003521A - Un proceso para la resolucion quiral de 1,3-oxatiolanos 2 sustituidos 4-sustituidos. - Google Patents

Un proceso para la resolucion quiral de 1,3-oxatiolanos 2 sustituidos 4-sustituidos.

Info

Publication number
MX2010003521A
MX2010003521A MX2010003521A MX2010003521A MX2010003521A MX 2010003521 A MX2010003521 A MX 2010003521A MX 2010003521 A MX2010003521 A MX 2010003521A MX 2010003521 A MX2010003521 A MX 2010003521A MX 2010003521 A MX2010003521 A MX 2010003521A
Authority
MX
Mexico
Prior art keywords
substituted
oxathiolanes
chiral resolution
derivatives
relates
Prior art date
Application number
MX2010003521A
Other languages
English (en)
Inventor
Widanagamage Ruwansiri Epa
Sebastian Mario Marcuccio
John Joseph Deadman
Original Assignee
Avexa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007905335A external-priority patent/AU2007905335A0/en
Application filed by Avexa Ltd filed Critical Avexa Ltd
Publication of MX2010003521A publication Critical patent/MX2010003521A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invenci?n se relaciona a un proceso novedoso para la resoluci?n quiral de 1,3-oxatiolanos 2-sustituidos 4-sustituidos y derivados de los mismos. La presente invenci?n tambi?n se relaciona a derivados de 1,3-oxatiolanos 2-sustituidos 4-sustituidos novedosos.
MX2010003521A 2007-09-28 2008-09-26 Un proceso para la resolucion quiral de 1,3-oxatiolanos 2 sustituidos 4-sustituidos. MX2010003521A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007905335A AU2007905335A0 (en) 2007-09-28 A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
US98125207P 2007-10-19 2007-10-19
PCT/AU2008/001433 WO2009039582A1 (en) 2007-09-28 2008-09-26 A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes

Publications (1)

Publication Number Publication Date
MX2010003521A true MX2010003521A (es) 2010-04-27

Family

ID=40510677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003521A MX2010003521A (es) 2007-09-28 2008-09-26 Un proceso para la resolucion quiral de 1,3-oxatiolanos 2 sustituidos 4-sustituidos.

Country Status (16)

Country Link
US (1) US8318934B2 (es)
EP (1) EP2190839B1 (es)
JP (1) JP5577251B2 (es)
KR (1) KR101374635B1 (es)
CN (1) CN101842370B (es)
AU (1) AU2008303073B2 (es)
BR (1) BRPI0817481A2 (es)
CA (1) CA2700653C (es)
ES (1) ES2542154T3 (es)
IL (1) IL204596A (es)
IN (1) IN2015DN02599A (es)
MX (1) MX2010003521A (es)
NZ (1) NZ584193A (es)
RU (1) RU2494098C2 (es)
WO (1) WO2009039582A1 (es)
ZA (1) ZA201001951B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
RU2244712C2 (ru) * 1998-08-12 2005-01-20 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиоланового нуклеозида, способ получения производного 1,3-оксатиоланил-5-она
EP1632490B1 (en) * 2001-06-15 2007-08-22 Shire Biochem Inc. Stereoselective method for the preparation of nucleoside analogues
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
WO2006096954A1 (en) * 2005-03-14 2006-09-21 Shire Biochem Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
KR20070080108A (ko) * 2006-02-06 2007-08-09 주식회사종근당 질소의 알파 위치에 비대칭탄소가 있는 라세믹 유도체의광학 이성질체 분리 방법

Also Published As

Publication number Publication date
AU2008303073B2 (en) 2012-08-09
CA2700653C (en) 2013-11-26
RU2010116776A (ru) 2011-11-10
NZ584193A (en) 2011-07-29
CN101842370A (zh) 2010-09-22
EP2190839A4 (en) 2011-10-26
EP2190839B1 (en) 2015-04-15
IL204596A (en) 2013-08-29
JP5577251B2 (ja) 2014-08-20
KR20100075964A (ko) 2010-07-05
CA2700653A1 (en) 2009-04-02
BRPI0817481A2 (pt) 2017-05-16
ES2542154T3 (es) 2015-07-31
KR101374635B1 (ko) 2014-03-14
US8318934B2 (en) 2012-11-27
CN101842370B (zh) 2014-02-19
AU2008303073A1 (en) 2009-04-02
EP2190839A1 (en) 2010-06-02
JP2010540467A (ja) 2010-12-24
ZA201001951B (en) 2011-05-25
IL204596A0 (en) 2010-11-30
WO2009039582A1 (en) 2009-04-02
US20100305321A1 (en) 2010-12-02
IN2015DN02599A (es) 2015-09-18
RU2494098C2 (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
MX2007014172A (es) Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
HK1145682A1 (en) Indolinone derivatives and process for their manufacture
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
MA32296B1 (fr) Derives de piperidine 3,4-substitues comme inhibiteurs de la renine
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
SI2060568T1 (sl) Polimorfi enantiomerno äśistega erdosteina
ZA201000394B (en) Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
MX2007013872A (es) Procedimiento para la produccion de 4-bifenililazetidina-2-onas.
ZA201009160B (en) Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
NO20065157L (no) Biotransformasjon av colchicinoidforbindelser
MX2009013921A (es) Material refractario sin forma, un proceso para producir un material refractario sin forma, humedo como la tierra, y al uso del material refractario sin forma.
MX345142B (es) Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina.
SI2225232T1 (sl) Postopek za pripravo substituiranih 1,3-oksatiolanov
IN2015DN02599A (es)
WO2009152474A3 (en) Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
MX2010003056A (es) Polimorfos de valomaciclovir.
WO2008061238A3 (en) Processes for production of 4-biphenylyazetidin-2-ones
GB0711250D0 (en) Furanose derivatives
TW200640856A (en) Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzylether derivatives
MX2009014191A (es) Procedimiento para la preparacion de derivados de dioxazina.
AU2007905335A0 (en) A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
MX2009003196A (es) Proceso para la preparacion de y-butirolactonas.

Legal Events

Date Code Title Description
FG Grant or registration